BioVaxys Technology Corp. C.BIOV

BIOV FOUNDER &CEO MR KOVAN PRESENTING DEC 4/ONCOLOGY CONF

[Humanist]

WOW THATS A BIG DEAL , HE OBVIOUSLY HAS BIG/GOOD INFO TO SHARE TO MAJOR INVESTORS.. GLTA 

BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference

by @newswire on 5 Dec 2022, 08:00   

VANCOUVER, BC, Dec. 5, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief Operating Officer Kenneth Kovan will be presenting at the MedInvest Oncology Investor Conference held in New York City on December 14-15, 2022. 
 
In partnership with the National Foundation for Cancer Research, the MedInvest Oncology Investor Conference is the preeminent indication-specific investor conference. The attendees are active investors in the oncology space and oncology-focused companies seeking investment and partnering opportunities, and include leading life science and oncology venture capitalists, family offices, pharma executives, private and public cancer companies and foundations. The National Cancer Institute is this year's Conference Presenting Partner, with speakers such as Greg Simon, who recently was the President of the Biden Cancer "Moonshot" Initiative, leading immunologists and oncologists from Memorial Sloan Kettering and other institutions, and global pharma R&D.

Details of the presentation are as follows:

When: Wednesday, December 14, 2022 @ 4:10PM EST

Where: Dorsey & Whitney LLP, 51 West 52nd Street, New York, NY

"BioVaxys is honored to be selected to speak at the MedInvest Oncology Investor Conference alongside a prestigious group of oncologists, investors, and life science companies. We look forward to sharing how we are leveraging our haptenized protein platform to create autologous cancer immunotherapies for ovarian cancer and other malignancies," said Mr. James Passin, CEO and Co-Founder of BioVaxys.

Mr. Kovan has over 30 years of experience in biopharma. Prior to founding BioVaxys Technology Corp., he served as Corporate Development Partner with gene editing leader Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012. He is an experienced former biotech CEO, and founder of biotechnology companies including Avax Technologies, Inc. Mr. Kovan's professional background includes technology transfer with Thomas Jefferson University, Strategic Marketing with SmithKline Beecham, and Global New Product Development with Wyeth-Ayerst. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets and led pharma development projects in Europe.
 

[bomdrou99]

Put in your diary. The price will go up quickly after this conference. The potential is huge and our patience will finally pay off. Buy at this price and you will quickly double it. And even more.

[SuperTrader1970]

Lets see the Buyers!!!! Bring it on!